Dysregulation of RAD51 is closely associated with tumourigenesis in multiple cancers, including breast [15], hepatocellular [8] and pancreatic carcinomas [11], with its overexpression frequently correlating with aggressive tumour behaviour, therapeutic resistance and poor prognosis. Here, RAD51 is linked to cancer.